The FDA on January 22, 2021 approved the combination of OPDIVO® (Nivolumab) and CABOMETYX® (Cabozantinib) as first line treatment for patients with advanced Renal Cell Carcinoma (RCC). OPDIVO® is a product of Bristol-Myers Squibb Co. and CABOMETYX® is a product of Exelixis, Inc.
Bottom Ad
Advertisement
Subscribe
